From IgE to clinical trials of allergic rhinitis

Expert Review of Clinical Immunology

Volumn 11, Issue 12, 2015, Pages 1321-1333

  Ciprandi, Giorgio ^a   Marseglia, Gian Luigi ^b   Castagnoli, Riccardo ^b   Valsecchi, Chiara ^b   Tagliacarne, Carlotta ^b   Caimmi, Silvia ^b   Licari, Amelia ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

allergen immunotherapy; allergic rhinitis; IgE; omalizumab; sublingual immunotherapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB;

ALLERGIC RHINITIS; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG POTENTIATION; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TABLET; CHEMISTRY; DESENSITIZATION; IMMUNOLOGY; RHINITIS, ALLERGIC;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; RHINITIS, ALLERGIC;

EID: 84947032434     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1086645     Document Type: Review

References (97)

1. Stanworth DR. The discovery of IgE. Allergy 1993;48:67-71
2. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007;7: 365-78
3. Zheng Y, Shopes B, Holowka D, et al. Conformations of IgE bound to its receptor Fc epsilon RI and in solution. Biochemistry 1991;30:9125-32
4. Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol 2014;14:247-59
5. Conrad DH, Ford JW, Sturgill JL, et al. CD23: an overlooked regulator of allergic disease. Curr Allergy Asthma Rep 2007;7: 331-7
6. Acharya M, Borland G, Edkins AL, et al. CD23/FcRII: molecular multi-tasking. Clin Exp Immunol 2010;162:12-23
7. Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 2003;21: 579-628
8. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;8: 205-17
9. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
10. Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013;68: 1102-16
11. Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 2007;19: 711-20
12. Naclerio RM. Allergic rhinitis. N Engl J Med 1991;325:860-9
13. Lambrecht BN. Allergen uptake and presentation by dendritic cells. Curr Opin Allergy Clin Immunol 2001;1:51-9
14. Durham SR, Ying S, Varney VA, et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992;148:2390-4
15. Takhar P, Smurthwaite L, Coker HA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005;174(8):5024-32
16. Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002;2:231-8
17. Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. Lancet 2011;378:2112-22
18. Ciprandi G, Caimmi D, Miraglia Del Giudice M, et al. Recent developments in United airways disease. Allergy Asthma Immunol Res 2012;4:171-7
19. Ciprandi G, Ricciardolo FL, Schiavetti I, et al. Allergic rhinitis phenotypes based on bronchial hyperreactivity to methacholine. Am J Rhinol Allergy 2014;28:214-18
20. Licari A, Ciprandi G, Marseglia A, et al. Current recommendations and emerging options for the treatment of allergic rhinitis. Expert Rev Clin Immunol 2014;10:1337-47
21. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11: 586-93
22. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American academy of allergy, asthma & Immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96.e3
23. Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2012;12(1):1-6
24. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J 2015;8:17
25. Soyka MB, van de Veen W, Holzmann D, et al. Scientific foundations of allergen-specific immunotherapy for allergic disease. Chest 2014;146:1347-57
26. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621-3
27. Lou W, Wang C, Wang Y, et al. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol 2012;23:140-9
28. Pree I, Reisinger J, Focke M, et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007;179:5309-16
29. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-60
30. van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-52
31. Cavkaytar O, Akdis CA, Akdis M. Modulation of immune responses by immunotherapy in allergic diseases. Curr Opin Pharmacol 2014;17:30-7
32. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011;127:509-16
33. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512-518.e2
34. Aasbjerg K, Backer V, Lund G, et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417-28
35. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6
36. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review. Pediatrics 2013;131: 1155-67
37. La Rosa M, Lionetti E, Leonardi S, et al. Specific immunotherapy in children: The evidence. Int J Immunopathol Pharmacol 2011;24:69-78
38. Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 2013;13:933-45
39. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65
40. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54
41. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64:1728-36
42. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93
43. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274-80
44. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134-40
45. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and comorbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271-9
46. Kamin W, Kopp MV, Erdnuess F. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21:e160-5
47. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120:688-95
48. Noon L. Prophylactic inoculation against hayfever. Lancet 1911;1:1572
49. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
50. Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010 (12):CD002893
51. Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66: 740-52
52. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-6
53. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
54. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immuno-therapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
55. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120: 1338-45
56. Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009;39:387-93
57. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73
58. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
59. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: The ECRIT study. Allergy 2009;64:179-86
60. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract 2014;2:144-9
61. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:483-91
62. Ciprandi G, Fenoglio D, Cirillo I, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 2007;28:40-3
63. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009;103:451-9
64. Gangl K, Niederberger V, Valenta R. Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis. Clin Exp Allergy 2013;43: 1202-16
65. EMA. Committee for Medicinal Products for human use (CHMP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. London, 20 November 2008. Doc. Ref. CHMP/EWP/18504/2006
66. EMA. Committee for Medicinal Products for human use (CHMP). Guideline on allergen products standardization and quality issues London, 20 November 2008. Doc. Ref. CHMP/BWP/304831/2007
67. A Trial of the ALK grass tablet in subjects with hayfever. Available from: https://clinicaltrials.gov/ct2/show/NCT00227279
68. Senna GE, Calderon M, Milani M. Allergy immunotherapy tablet: Grazax for the treatment of grass pollen allergy. Expert Rev Clin Immunol 2011;7:21-7
69. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80
70. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90
71. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512-18
72. Efficacy and safety of grazax in children. Available from: https://clinicaltrials.gov/ct2/show/NCT00408616
73. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71
74. Tolerability of grazax in patients with hayfever in real life settings (GRAAL). Available from: https://clinicaltrials.gov/ct2/show/NCT01433510
75. Wessel F, Chartier A, Meunier JP, Magnan A. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX) in a real-life setting for three consecutive seasons-The GRAAL trial. Clin Drug Investig 2012;32:451-63
76. Efficacy and safety of sublingual tablets of grass pollen allergen extract. Available from: https://clinicaltrials.gov/ct2/show/NCT00619827
77. Horak F, Jaeger S, Worm M, et al. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy 2008;39:394-400
78. Safety and efficacy of sublingual immunotherapy (SLIT) tablets in grass pollen rhinoconjunctivitis. Available from: https://clinicaltrials.gov/ct2/show/NCT00367640
79. Efficacy and safety of 300 IR sublingual immunotherapy (SLIT) tablets in children suffering from grass pollen rhinoconjunctivitis. Available from: https://clinicaltrials.gov/ct2/show/NCT00409409
80. Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Exp Opin Drug Saf 2015;14:777-88
81. Phase III study to assess the long term efficacy, carry-over effect and safety of 300 IR sublingual immunotherapy tablets. Available from: https://clinicaltrials.gov/ct2/show/NCT00418379
82. Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Exp Rev Clin Immunol 2014;10:1309-24
83. Sastre J, Landivar ME, Ruiz-García M, et al. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012;67: 709-11
84. Ciprandi G. A major step forward for sublingual immunotherapy: The quality of 5-grass pollen tablet is recognized also in Italy. J Asthma Allergy 2015;8:25-7
85. Nelson HS. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Exp Rev Clin Immunol 2014;10:1437-51
86. Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;1:CD003559
87. Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs 2014;16:491-502
88. Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Exp Opin Drug Discov 2015;1-10
89. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100: 110-21
90. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9
91. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 2001;286:2956-7
92. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-7
93. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
94. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006;55:379-86
95. Nagakura T, Ogino S, Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008;38:329-37
96. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: A systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014;2:332-40.e1
97. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review. Chest 2011;139:28-35